The weight loss medication market is shaping up to be a duopoly of Eli Lilly and Novo Nordisk, analysts said.
Eli Lilly bested investors' super-high expectations at the American Diabetes Association conference this week, cementing its leadership in metabolic medicine and prompting Wall Street analysts to take another look at their sales forecasts. Across the board, analysts said the news is likely to lend support Lillto y shares, which have already popped more than 26% this year. At least one analyst felt the news was strong enough to immediatey adjust his long-term sales forecast.
"We forecast the total Mounjaro + Orforglipron + Retatrutide portfolio reaching $48-49bn over the 2030-2032 period, with declining pricing." Gould said orforglipron appears to be a "best-in-class" oral medication. Many analysts see an oral GLP-1 medication as helpful to patients who don't want to give themselves an injection. Analysts also say an oral medication will help ease supply bottlenecks that have been a problem in the category.
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Eli Lilly Experimental Obesity Drug Could Beat Rivals in Total Weight Loss for PatientsObese or overweight patients who took Eli Lilly’s retatrutide lost 58 pounds on average, the pharmaceutical company said in a mid-stage clinical trial.
Read more »
Next-generation drug from Eli Lilly boosts weight loss to 24%, highest yet seen in trialsIn addition to the 24% average weight loss on the highest dose in the trial – about 58 pounds over 11 months – a quarter of patients on that dose experienced weight loss of at least 30%.
Read more »
Breakingviews - Eli Lilly gorges on obesity optionsEli Lilly has filled its plate with potential obesity treatments, unveiling data from two more on Monday. One offers the convenience of a pill; the other, with the scientific name retatrutide, led to patients losing an astonishing 24% of their weight at the highest dose.
Read more »
Daily pill from Eli Lilly leads to 15% weight loss in midstage study, rivaling Wegovy results without the shotEli Lilly’s experimental pill for weight loss helped people lose an average of 15% of their body weight after 36 weeks on the highest dose in a midstage trial.
Read more »
Experimental drug could offer more weight loss than any drug now on the market, study findsThe experimental drug, retatrutide, helped people lose, on average, about 24% of their body weight, the equivalent of about 58 pounds, in a mid-stage clinical trial, the company says.
Read more »
Woman in clinical trial for new weight loss drug lost 60 pounds in less than a yearThe new findings, according to Dr. Shauna Levy, a specialist in obesity medicine and the medical director of the Tulane Bariatric Center in New Orleans, are “mind-blowing.”
Read more »